Mark Timney

photo of Mark Timney

Mark Timney


Mark Timney has deep experience in the biopharmaceutical industry. He has repeatedly distinguished himself as a corporate leader who delivers value for patients and shareholders. In addition to his role as Chairman of the Board with Blade, Mark currently serves as Chief Executive Officer at Attralus and a board member at Sarissa Capital Acquisition Corp. (NASDAQ: SRSAU). He is also a strategic advisor to health care companies and investment groups.

Throughout a career defined by deep operational and commercial experience, Mark has led significant acquisitions and divestitures; reshaped country and global business operations; launched numerous breakthrough medicines; delivered growth strategies to achieve market leadership; and played key roles in pipeline governance. He has held senior roles in companies that include The Medicines Company, Merck & Co., Purdue Pharmaceuticals, Zeneca Group, ICI Pharmaceuticals and Roussel Labs, and has led markets that include the United States, Japan, South Korea, Australia and New Zealand.

Mark’s most recent executive role was CEO and Board member of The Medicines Company (NASDAQ: MDCO) which was subsequently sold to Novartis (NYSE: NVS) for $9.7B.